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r John D. Mitchell (Denver, Colo). Doug, I want to congratulate
ou and your coinvestigators on this very nice study, article, and
resentation. Two of the biggest problems with surgical LVRS are
he attendant morbidity and mortality associated with the proce-
ure and the cost. One would hope that the development of
ess-invasive endobronchial therapies, such as this valve, could
ead to expansion of the subgroup of patients with emphysema
ho might benefit from LVRS with less risk and at a lesser cost.
I just have a couple of questions for you. First, I wonder
hether you could comment on some of the technical aspects of
alve implantation. Is general anesthesia necessary? Are some
egments and subsegments harder to instrument than others? And
s this what led to considerable variation or range of the procedure
imes seen in the study?
Dr Wood. In terms of the first part of that question, general
nesthetic is probably not necessary. We chose to use general
nesthesia in this initial experience to decrease the possible tech-
ical difficulties and variability of doing this in an awake patient.
ll that said, I think that even later, as we gain experience, there
till might be some benefit of doing it with a general anesthetic.
here is a lot of airway manipulation of multiple segments, and it
s very easy to do with a patient anesthetized. I think that the aspect
f cough or respiratory movement might make some of those
djustments and placement of the valve more difficult. I do not
ave experience with that yet, but I can anticipate that that might
e the case.
In terms of segments that are more difficult: yes, there are. As
ou get more acute angles into the anterior segments of both upper
obes, those can sometimes be difficult angles to achieve. Fortu-
ately, the fact that we have a delivery catheter that goes through
he flexible bronchoscope and can be visualized going into that
egment does make it easier and that has become easier, for
xample, in the last 8 patients, as I describe. Still, sometimes the
ngles are difficult in the anterior segments.
Does that relate to the variability in procedure time? Possibly.
am not sure. I think that obviously this is an initial experience,
nd therefore the investigators as they were first doing this were
ompletely new to the procedure, so that this involves all of the
earning curve of doing the procedure as well, which I think we
ave gotten better at, but I think we would have to have substan-
ially more experience to know whether we can decrease that time
eliably.
Dr Mitchell. Second, were you surprised at the relative lack of
omplications caused by the valves? Specifically, I am interested
n either valve migration or postobstructive pneumonia.
Could you comment on the hyperplastic tissue response that
as seen associated with some of the valves several months aftermplantation?
ic and Cardiovascular Surgery ● Volume 133, Number 1 71
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G
TSDr Wood. That is a good question. I am somewhat surprised.
expected first of all an instance of pneumothorax, which has been
een in similar trials of the Emphasis valve. They have had a
ignificant incidence of pneumothorax, which we did not have in
his initial phase A of our pilot trial, but I would have expected a
ig concern in plugging the airways of a patient with COPD as
pposed to obstructive pneumonia. The valve is obviously pur-
osely designed to allow mucus secretions to pass proximal to the
alve, yet still it is functionally obstructed, and I would expect an
nstance of postobstructive pneumonia distal to these valves that,
ortunately, we did not see. With additional time, we might.
In terms of the hyperplastic tissue, I have now removed valves
n 2 of my patients out 1 year because they have not had a
ubstantial improvement and now wanted to be considered for
VRS, and we wanted to remove the valves before that. They have
ad variable amounts of hyperplastic tissue obscuring the valves.
ortunately, we still have been able to remove all valves—100% of
he ones that I have done even at 12 months—but some of them do
ave hyperplastic tissue proximal to the valve.
Dr Mitchell. Third, you were able to report that a substantial
umber of patients had a meaningful change in their health-related
uality of life comparable with that seen in the NETT. When you
id that comparison, did you use patients in the NETT with similar
natomic findings to those in your study?
Dr Wood. No, and it is not really possible to do that because
hat requires access to the primary data, which are not yet released
or the NETT, to be able to try to stratify it to that degree.
herefore this is just a general NETT population.
Dr Mitchell. Finally, as I mentioned before, it would be nice if
he use of these less-invasive technologies could expand the pool
f patients with emphysema eligible for LVRS. In this study you
imited your patient population to those who met generally the
ETT criteria and had upper lobe–predominant disease, perhaps
he group that you would expect to have the best outcome from this
rocedure. Could you comment or maybe speculate how this
evice might work in those with non–upper lobe disease, those
eemed high risk by NETT criteria, perhaps even those with
omogeneous disease and those with significant medical comor-
idities?
Thank you very much. I enjoyed the article.
Dr Wood. Thank you, John. In terms of speculation and the
eason for selecting this most favorable subset as an initial pilot
eries, you can probably understand the desire to do that when your
nitial study is a safety study looking at feasibility more than
ffectiveness. That is the reason for the stringent selection criteria
n this phase. You are right that if in this phase it proves to be
ffective and a pivotal trial, then I think we should expand the
ndications and look at patients who otherwise might have contra-
ndications to LVRS, as I introduced at the beginning of this, who
ight benefit from this or other forms of endobronchial therapy.
Dr Jerome McDonald (Lakewood, Wash). One of my con-
erns about this particular procedure over LVRS is that you have
eveloped an obligate shunt, and I was wondering whether there is
oing to be any assessment in your future trials of efficacy with
ny perfusion studies or any way to assess whether an obligate
hunt is going to decrease some of the effectiveness or efficacy of
he procedure. t
2 The Journal of Thoracic and Cardiovascular Surgery ● JanuaDr Wood. In fact, most likely what has happened is the
pposite of what you are talking about, which is an improvement
n ventilation-perfusion match rather than a worsening. In fact, if
ou look at these patients, they have such low compliance in their
pper lung fields that they are preferentially ventilated but very
oorly perfused. Therefore, in fact, one of the ways that valves
ight be effective in improving patient quality of life is actually by
mproving ventilation-perfusion mismatch by decreasing the ven-
ilation in an area that is already underperfused.
Dr Donald Low (Seattle, Wash). Doug, I enjoyed the article. I
ould specifically like to ask you a question regarding something
hat is in your abstract regarding follow-up bronchoscopy. It looks
ike that was a routine aspect of your ongoing assessment in these
atients. I would like you to just let us know when this was done,
nd interestingly, I note that 17 patients—more than half of your
atients—either had valve revision or additional valves placed.
he valve revision issue is interesting considering how low your
igration or other problems were. Could you tell us a little bit
bout what that valve revision was all about and what indicated the
eed for additional valves in selected patients on the follow-up
ronchoscopy?
Dr Wood. Very astute of you, Don. I actually left that out
ecause of lack of time, but in fact the protocol required a 1-month
ollow-up bronchoscopy that we wanted to do to assess valve
lacement and adequacy of seating of each of the valves and lack
f migration, so that was a part of the planned protocol. All
atients had a follow-up bronchoscopy at 1 month. Of the 30
atients, 17 of them had some revisions of their valves at that
-month planned bronchoscopy. Some of them had valves re-
oved. Some of them had valves removed and replaced, and some
ad additional valves placed. The most common rationale for each
f them was not any valve migration but an appearance of a valve
hat looked like it might not be occlusive because of angulation or
ecause of a wrinkle in the valve membrane that we thought could
ossibly be improved by a different size or better seating of the
alves, and therefore those valves were removed and replaced.
hat was the most common indication. The reason for new valves
eing placed is sometimes that we were cautious in the initial
lacement and did not necessarily occlude every segment that we
ould like to and with more confidence would treat additional
egments at the second bronchoscopy. Actually, after the second
ronchoscopy, there were 10 more valves than the 184 that I
resented in the article here.
Dr Henning Gaissert (Boston, Mass). I very much enjoyed
our presentation, Doug. In other areas of the airway, when pros-
hetic devices are being placed, it is not necessarily clinical infec-
ion but colonization with particular organisms that indicate a
igher risk of long-term infection, these organisms being particu-
arly Staphylococcus aureus and Pseudomonas species. Have you
one any culturing of the airway to see whether you get these
pecific organisms?
Dr Wood. No, we have not.
Dr Gaissert. Thank you. I very much enjoyed it.
Unidentified speaker. Nicely done, Doug. As to volume re-
uction surgery, one of the ways it works is it reduces the size of
he lungs and mechanics improve and so on. Do you have any idea
hether you are actually reducing the size of these lungs withhese valves? Do you see it?
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TSDr Wood. The answer to that is, at least in this pilot experience
ith the first 30 patients, no. We are not reducing the size of the
ungs, and that is kind of what my next-to-last slide was about. We
ave different mechanisms working here than mechanisms that we
hought were going to be working when we try to duplicate LVRS.
learly the patients are having an improvement in quality of life,
ut the objective measures that we have used in LVRS are not
ecessarily representing the reason that these patients are having
n improvement. It might be things like dynamic hyperinflation. I
ill say just as a teaser that we have moved into a second phase of
his study already and with a slightly different valve design and
ome more aggressive treatment, and in that group we are starting
o see volume reduction as well with the atelectasis that we would
ind of like to see. Surgically what we were thinking that we were
iming for is an atelectasis developing in the upper lobes to mimic
he effects of LVRS, but at least in these first 30 patients, that was
ot seen to any reliable degree.
Dr Joseph Shrager (Philadelphia, Pa). Doug, how is it that
hese did not have surgical LVRS? In other words, did they have
o be assessed by a surgeon or decline having surgical LVRS,
iven that you have a proved therapy and now have an experi-
ental therapy?
Dr Wood. It is a good question. Some of these patients wereThe Journal of Thoracprevious coronary artery bypass graft and was not a candidate
or LVRS but would very much be a candidate for an endo-
ronchial therapy. Other patients were candidates for either,
nd they were all in centers that could do LVRS, obviously in
urgical centers like ours. They were all counseled about the
hoices of LVRS or involvement in this clinical trial. At the
ther centers, with the pulmonary physicians as principal in-
estigators, there was the same counseling. The effort was to
rovide patients with counseling about all of their options,
ncluding surgical volume reduction.
Dr Shrager. The other issue is, can you speculate about
hy—you touched on this a little bit—the FEV1 is not im-
roved, whereas the quality of life is improved?
Dr Wood. Well, the FEV1 surprisingly was not improved
here quality of life was and that is where I think our dilemma
s, except we know that FEV1 is not a reliable surrogate for
mprovement after LVRS either, with a substantial number of
atients having much more significant improvement in their
unctional capacity and quality of life that is not well repre-
ented by FEV1. Our problem is that we are not yet very good
t measuring the right measurement, and FEV1 is common, so
e use it a lot, but it is not a very reliable measure of efficacyot candidates for LVRS. For example, one of my patients had in these types of treatments for emphysema.
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